BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 9765504)

  • 1. Analysis of random recombination between human MDR1 and mouse mdr1a cDNA in a pHaMDR-dihydrofolate reductase bicistronic expression system.
    Shoshani T; Zhang S; Dey S; Pastan I; Gottesman MM
    Mol Pharmacol; 1998 Oct; 54(4):623-30. PubMed ID: 9765504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
    Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
    Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
    Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
    Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single amino acid residue contributes to distinct mechanisms of inhibition of the human multidrug transporter by stereoisomers of the dopamine receptor antagonist flupentixol.
    Dey S; Hafkemeyer P; Pastan I; Gottesman MM
    Biochemistry; 1999 May; 38(20):6630-9. PubMed ID: 10350482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution of the human MDR3 P-glycoprotein.
    Smit JJ; Schinkel AH; Mol CA; Majoor D; Mooi WJ; Jongsma AP; Lincke CR; Borst P
    Lab Invest; 1994 Nov; 71(5):638-49. PubMed ID: 7734012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes.
    Schuetz EG; Umbenhauer DR; Yasuda K; Brimer C; Nguyen L; Relling MV; Schuetz JD; Schinkel AH
    Mol Pharmacol; 2000 Jan; 57(1):188-97. PubMed ID: 10617694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
    Lee CG; Gottesman MM; Cardarelli CO; Ramachandra M; Jeang KT; Ambudkar SV; Pastan I; Dey S
    Biochemistry; 1998 Mar; 37(11):3594-601. PubMed ID: 9530286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
    Findling-Kagan S; Sivan H; Ostrovsky O; Nagler A; Galski H
    Leuk Res; 2005 Apr; 29(4):407-14. PubMed ID: 15725475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
    Kang CD; Ahn BK; Jeong CS; Kim KW; Lee HJ; Yoo SD; Chung BS; Kim SH
    Exp Cell Res; 2000 Apr; 256(1):300-7. PubMed ID: 10739677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport.
    Sivapackiam J; Harpstrite SE; Prior JL; Gu H; Rath NP; Sharma V
    Dalton Trans; 2010 Jul; 39(25):5842-50. PubMed ID: 20505882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and functional characterization of the mouse multidrug resistance gene family.
    Dhir R; Buschman E; Gros P
    Bull Cancer; 1990; 77(11):1125-9. PubMed ID: 1980424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
    Pichler A; Zelcer N; Prior JL; Kuil AJ; Piwnica-Worms D
    Clin Cancer Res; 2005 Jun; 11(12):4487-94. PubMed ID: 15958634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
    Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
    Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inability of the mouse mdr2 gene to confer multidrug resistance is linked to reduced drug binding to the protein.
    Buschman E; Gros P
    Cancer Res; 1994 Sep; 54(18):4892-8. PubMed ID: 7915194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells.
    Anuchapreeda S; Leechanachai P; Smith MM; Ambudkar SV; Limtrakul PN
    Biochem Pharmacol; 2002 Aug; 64(4):573-82. PubMed ID: 12167476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy.
    Sauna ZE; Andrus MB; Turner TM; Ambudkar SV
    Biochemistry; 2004 Mar; 43(8):2262-71. PubMed ID: 14979722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting P-glycoprotein transport.
    Barthomeuf C; Demeule M; Grassi J; Saidkhodjaev A; Beliveau R
    Planta Med; 2006 Jun; 72(7):634-9. PubMed ID: 16739070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
    Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; BĂ©liveau R
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
    Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
    Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.